Floatz logo

Montanide Isa 51

Stage IV Melanoma

Ludwig Institute for Cancer ResearchPhase 2Dormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

104 Active assets in the Stage IV Melanoma cohort.

Asset / SponsorPhaseRating
Cediranib
M.D. Anderson Cancer Center
Phase 2BBB
DACARBAZINE
Shanghai Junshi Bioscience Co., Ltd.
Phase 4BBB
Ifa
Craig L Slingluff, Jr
Phase 2BB
Nivolumab
Bristol-Myers Squibb
Phase 4BB
TIL
East Metropolitan Health Service, Australia
Phase 2BB

View all 50 →

Same molecule, other indications

Montanide Isa 51 is also rated in:

Acute Myelogenous Leukemia (AML)Dormant
BB
Indicative ·
70 / 100
View asset →
melanomaDormant
BB
Indicative ·
68 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →